Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively built its IO2.0 + ADC2.0 therapeutic matrix, and continued orderly development of bispecific antibodies in major chronic disease areas, including autoimmune, respiratory, and central nervous system (CNS) disorders Commercialization Reaches Record High Commercial sales revenue for the first half of 2026 reached approximately RMB 1,803.2 million, representing a 28.7% increase year-over-year.